EUVIMEDEUVIMED entdecken
Crossref

Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn’s Disease

Zhigang Wang, Yannick Hoffert, Wei Zhang, Wannee Kantasiripitak, Bram Verstockt, João Sabino, Marc Ferrante, Paul Declerck, Geert D'Haens, David Laharie, Séverine Vermeire, Erwin Dreesen

Clinical Gastroenterology and Hepatology · 2026-05 · 24 (5) · 1402-1412

DOI: 10.1016/j.cgh.2025.08.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-05. Verfasst von Zhigang Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Ustekinumab, Infliximab, Crohn Disease, Gastrointestinal Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Vlaamse regering, KU Leuven, FWO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Infliximab and ustekinumab clearance have been suggested as predictors of disease activity in patients with inflammatory bowel diseases. We aimed to investigate the benefits of clearance monitoring for predicting endoscopic outcomes in patients with Crohn's disease (CD). METHODS: Data from patients with moderate-to-severe CD starting infliximab (n = 108) and ustekinumab (n = 80) therapy were repurposed. Endoscopic remission (CD Endoscopic Index of Severity 50% reduction in Simple Endoscopic Score for CD) was assessed at w24 of ustekinumab therapy. We performed Bayesian forecasting to estimate time-varying mAb clearance using drug concentrations, covariates, and in-house developed population pharmacokinetics models. RESULTS: Patients achieving endoscopic remission at w12 had significantly lower infliximab clearance and higher infliximab serum trough concentrations (Ctrough) at w2 of standard 5 mg/kg infliximab induction therapy, than patients without endoscopic remission (P < .05). During infliximab maintenance therapy (with eventual dose optimizations), patients achieving endoscopic remission at w54 had significantly lower infliximab clearance (P < .001) but not higher infliximab Ctrough (P = .92) than those without remission. Moreover, infliximab clearance during maintenance had similar discriminative ability as fecal calprotectin (area under the receiver operating characteristics curve 0.63; 95% confidence interval, 0.56-0.69 vs 0.67; 95% confidence interval, 0.61-0.73, respectively). Ustekinumab clearance, but not Ctrough, was significantly different between endoscopic responders and nonresponders during standard ustekinumab induction and maintenance therapy (P < .05). CONCLUSIONS: Although Ctrough loses its ability to predict treatment response when doses are optimized or not administered by bodyweight, infliximab and ustekinumab clearance remains a reliable predictor for endoscopic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabInfliximabCrohn DiseaseGastrointestinal AgentsImmunologic FactorsHumansMaleFemaleAdultTreatment OutcomeMiddle AgedYoung AdultDrug Monitoring

Stichwörter der Autor:innen

Clearance MonitoringCrohn’s DiseaseInfliximabTherapeutic Drug MonitoringUstekinumab

Substanzen

UstekinumabInfliximabGastrointestinal AgentsImmunologic Factors

Autor:innen und Institutionen

  • Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • Department of Gastroenterology and Hepatology, UZ Leuven, Leuven, Belgium; Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
  • Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands.
  • CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-Gastroentérologie et Oncologie Digestive, Université de Bordeaux, F-33000 Bordeaux, France.
  • Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address: erwin.dreesen@kuleuven.be.

Förderung

  • Vlaamse regering
  • KU Leuven
  • FWO
  • University Hospitals

Zitieren

APA

Wang, Z., Hoffert, Y., Zhang, W., Kantasiripitak, W., Verstockt, B., Sabino, J., Ferrante, M., Declerck, P., D'Haens, G., Laharie, D., Vermeire, S., & Dreesen, E. (2026). Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn’s Disease. Clinical Gastroenterology and Hepatology, 24(5), 1402-1412. https://doi.org/10.1016/j.cgh.2025.08.030

Vancouver

Wang Z, Hoffert Y, Zhang W, Kantasiripitak W, Verstockt B, Sabino J, et al. Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn’s Disease. Clinical Gastroenterology and Hepatology. 2026;24(5):1402-1412. doi:10.1016/j.cgh.2025.08.030

BibTeX
@article{Wang2026,
  author = {Wang, Zhigang and Hoffert, Yannick and Zhang, Wei and Kantasiripitak, Wannee and Verstockt, Bram and Sabino, João and Ferrante, Marc and Declerck, Paul and D'Haens, Geert and Laharie, David and Vermeire, Séverine and Dreesen, Erwin},
  title = {Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn’s Disease},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {5},
  pages = {1402--1412},
  doi = {10.1016/j.cgh.2025.08.030}
}
Kostenlos starten →